{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:25:42Z","timestamp":1790738742590,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"DH | NIHR | Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.1038\/s41416-019-0570-y","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T23:04:25Z","timestamp":1568675065000},"page":"629-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Are we over-treating with checkpoint inhibitors?"],"prefix":"10.1038","volume":"121","author":[{"given":"Sarah","family":"Danson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"570_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.critrevonc.2018.07.002","volume":"129","author":"CRP da Veiga","year":"2018","unstructured":"da Veiga, C. R. P., da Veiga, C. P. & Drummond-Lage, A. P. Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies. Crit. Rev. Oncol. Hematol. 129, 133\u2013145 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"570_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R. et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol. 30, 582\u2013588 (2019).","journal-title":"Ann. Oncol."},{"key":"570_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med"},{"key":"570_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med"},{"key":"570_CR5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668\u20131674 (2018).","journal-title":"J. Clin. Oncol."},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicenter, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390, 1853\u20131862 (2017).","journal-title":"Lancet"},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.2017.76.8275","volume":"36","author":"NI Khushalani","year":"2018","unstructured":"Khushalani, N. I. Duration of anti-programmed death-1 therapy in advanced melanoma: how much of a good thing is enough? J. Clin. Oncol. 36, 1649\u20131653 (2018).","journal-title":"J. Clin. Oncol."},{"key":"570_CR8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldringer, S. M., Geukes Foppen, M. H., Hoejbergs, L. et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann. Oncol. 30, 1154\u20131161 (2019).","journal-title":"Ann. Oncol."},{"key":"570_CR9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"AC Tan","year":"2018","unstructured":"Tan, A. C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M. S. et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann. Oncol. 29, 2115\u20132120 (2018).","journal-title":"Ann. Oncol."},{"key":"570_CR10","doi-asserted-by":"crossref","unstructured":"Spigel D., McCleod M., Hussein M., Waterhouse D. M., Einhorn L., Horn L., et al. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 2017; 28, 461 (Suppl 5), abstract 12970 (2017).","DOI":"10.1093\/annonc\/mdx380.002"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0570-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:43Z","timestamp":1684616743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0570-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,10,15]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0570-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are co-applicants on the DANTE trial. S.D. has received conference and travel support from MSD, Pierre Fabre and BMS; and sat on advisory boards for MSD and BMS. P.C. has received speaker fees and sat on advisory boards for MSD, BMS, Novartis and Pierre Fabre. S.R. is CEO of the charity Melanoma Focus. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The DANTE study is funded by the National Institute for Health Research Health Technology Assessment (HTA) Programme (project number 15\/57\/66). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funder has not been involved in the writing of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}